• Pediatrix reaffirmed full-year 2026 Adjusted EBITDA guidance of $280 million to $300 million.
• Second-quarter payor mix held stable versus recent historical trends and internal expectations, avoiding the unfavorable shifts flagged elsewhere in healthcare.
• No material changes seen in other net revenue-related trends compared with recent periods.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pediatrix Medical Group Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607150650BIZWIRE_USPR_____20260715_BW262589) on July 15, 2026, and is solely responsible for the information contained therein.